52 Week Range
As of on the XETRA ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Bayer's Finerenone Meets Primary Endpoint In Phase III FIDELIO-DKD Renal Outcomes Study
Australia's ACCC Says Elanco’s Acquisition Of Bayer’s Animal Health Business Not Opposed
U.S. FDA Posts Interim Results For Postmarket Surveillance Study On Essure, A Permanently Implanted Birth Control Device For Women
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.
Chairman of the Supervisory Board
Chairman of the Management Board, Chief Executive Officer
Independent Vice Chairman of the Supervisory Board, Employee Representative
Wolfgang U. Nickl
Chief Financial Officer, Member of the Management Board
Member of the Management Board, Head of the Crop Science Division, Animal Health Business Unit
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* BAYER’S FINERENONE MEETS PRIMARY ENDPOINT IN PHASE III FIDELIO-DKD RENAL OUTCOMES STUDY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES
Bayer <BAYGn.DE> was forced on Wednesday to delay part of a proposed settlement of allegations that its widely used weedkiller Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims.
* IS IN AGREEMENT WITH COUNSEL REPRESENTING PROPOSED ROUNDUP SETTLEMENT CLASS ON THEIR DECISION TO WITHDRAW PENDING MOTION FOR PRELIMINARY APPROVAL OF PARTIES' ISSUE CLASS AGREEMENT
Bayer shares fell more 6% on Tuesday after a U.S. judge questioned part of the German company's proposed settlement to deal with future claims relating to allegations that its widely used weedkiller Roundup caused cancer.
Bayer shares dropped 6% on Tuesday after a U.S. judge questioned the German company's proposed settlement to deal with future claims relating to allegations that its widely-used weedkiller Roundup caused cancer.
Seeking to forestall further claims, Bayer AG is taking a risky bet that an independent scientific review will ultimately show that its widely used weed killer Roundup does not cause cancer, legal experts said.
Bayer AG, after more than a year of talks, agreed to pay as much as $10.9 billion to settle close to 100,000 U.S. lawsuits claiming that its widely-used weedkiller Roundup caused cancer, resolving litigation that has pummeled the company's share price.
Weitz & Luxenberg said on Wednesday it and other law firms reached a settlement with Bayer on behalf of almost one hundred thousand Americans who had been diagnosed with cancer after exposure to Monsanto's Roundup weedkiller.
* BAYER AG HAS SETTLED 95,000 U.S. ROUNDUP CANCER LAWSUITS FOR $10-$11 BILLION - SOURCE
Bayer AG on Wednesday said it agreed to settle U.S. lawsuits claiming that its widely-used weedkiller Roundup caused cancer for $10.1-10,9 billion. (Reporting by Ludwig Burger Editing by Edward Taylor)
Bayer AG is close to agreeing a settlement worth $8-10 billion over claims its glyphosate-based Roundup weedkiller causes cancer, German business daily Handelsblatt reported on Tuesday.
Germany's Bayer <BAYGn.DE> is set to reach a settlement this week with U.S. plaintiffs that claim its glyphosate-based weedkillers cause cancer, two people familiar with the matter told Reuters.
Germany's Bayer is close to agreeing a settlement over claims its glyphosate-based Roundup weedkiller causes cancer this week, two people familiar with the matter told Reuters.
Bayer AG is close to agreeing a settlement worth $8-10 billion with plaintiffs in a case over its glyphosate-based weedkiller, German business daily Handelsblatt reported on Tuesday.
A U.S. federal appeals court on Monday blocked California from requiring that Bayer AG label its glyphosate-based weed killer Roundup with a cancer warning, handing the company a victory in its ongoing litigation over the product.
Bayer AG won a court ruling blocking California from requiring the German-based company to tell consumers that a chemical in its Roundup herbicide is known to cause cancer, Bloomberg News reported on Monday.
* PORTOLA PHARMACEUTICALS - ON JUNE 12 GOT WRITTEN NOTICE OF TERMINATION FROM BAYER AG OF CLINICAL COLLABORATION AGREEMENT BY & BETWEEN CO, BAYER
Bayer AG said on Tuesday it will scrap a nearly $1 billion project to produce the chemical dicamba in the United States, but said the move is unrelated to a federal court decision that blocked sales of weed killers based on the product.
SGS SA <SGSN.S> aims to profit from increased testing for residue left on food by the main ingredient in Bayer AG's <BAYGn.DE> weedkiller Roundup, as the Swiss company said on Monday that nine of its laboratories won an advocacy group's certification.
* BAYER ANIMAL HEALTH AND BIOIBERICA COMPANION ANIMAL HEALTH HAVE SIGNED A STRATEGIC DISTRIBUTION AGREEMENT TO DISTRIBUTE AND MARKET SELECTED PRODUCTS FROM BIOIBERICA'S PORTFOLIO IN GERMANY, AUSTRIA, FRANCE, BELGIUM, THE NETHERLANDS AND KOREA, STARTING IN THE FIRST QUARTER...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.